# A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

> **NCT01453491** · PHASE1 · COMPLETED · sponsor: **Sirtris, a GSK Company** · enrollment: 17 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** SRT2104

## Key facts

- **NCT ID:** NCT01453491
- **Lead sponsor:** Sirtris, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-13
- **Primary completion:** 2013-03-18
- **Final completion:** 2013-03-18
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453491, "A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01453491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*